替吉奥为基础的化疗在消化道肿瘤中安全性的观察和分析  

Observation and analysis of safety in gastrointestinal cancer patients treated with S-1-based chemotherapy

作　　者：黄镜[1] 王向玲[2] 周一[1] 周爱萍[1] 陶云霞[1] 王金万[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院内科,北京100021 [2]山东大学齐鲁医院肿瘤防治中心化疗科,济南250012

出　　处：《癌症进展》2011年第6期707-710,717,共5页Oncology Progress

摘　　要：目的观察不同剂量替吉奥在消化道肿瘤患者中的耐受性和近期疗效。方法 44例消化道肿瘤患者,15例给予替吉奥80 mg/(m2.d),29例给予替吉奥50～70 mg/(m2.d)为基础的联合化疗方案,观察其不良反应及近期疗效。结果所有病例中9例(20.45%)发生Ⅲ/Ⅳ级血液学毒性,7例(15.90%)发生Ⅲ/Ⅳ级消化道毒性。80 mg/(m2.d)剂量组与50～70 mg/(m2.d)剂量组比较,Ⅲ/Ⅳ级血液学毒性发生率分别为33.33%和13.79%,Ⅲ/Ⅳ级消化道毒性发生率分别为46.67%和0,其中Ⅲ/Ⅳ级厌食发生率分别为40.00%和0。80 mg/(m2.d)剂量组Ⅲ/Ⅳ级消化道毒性发生率明显高于50～70 mg/(m2d)剂量组。在可评价的胃或贲门癌病例中,替吉奥80 mg/(m2.d)剂量组总有效率57.14%,50～70 mg/(m2.d)剂量组总有效率60.00%。结论消化道肿瘤中替吉奥50～70 mg/(m2.d)耐受性更好,不良反应轻,疗效确切,可推荐该剂量用于消化道肿瘤的联合化疗。Objective To investigate the short-term efficacy and safety of S-1-based chemotherapy in the treatment of gastrointestinal（GI） cancer at different doses.Methods A total of 44 patients with GI cancer were treated with S-1-based chemotherapy.The doses of S-1 were 80mg/m2/d in 15 patients and 50-70mg/m2/d in the other 29 patients.The side effects were carefully observed and the response rates were evaluated in time.Results The grade 3/4 hematological toxicities were seen in 9（20.45%） patients.The incidence rate was 33.33% in patients treated with high dose and 13.97% in patients with low dose.The grade 3/4 gastrointestinal toxicities were seen in 7（15.90%） patients.The incidence rates were 46.67% in high dose group and 0% in low dose group.The grade 3/4 anorexia was seen in 6（40.00%） patients in high dose group and 0 in low dose group.Compared with low dose group,the high dose group suffered higher GI toxicities.Meanwhile,the response rate were 57.14% in high dose group and 60.00% in low dose group,while S-1 was used in patients with gastric cancer and gastroesophageal junction cancer that were assessable for the response.Conclusion S-1 is well-tolerated at the dose of 50-70mg/m2/d in patients with GI cancer.S-1 given at the dose of 50-70mg/m2/d can achieve promising response rate and mild toxicity,and might be recommended in combined chemotherapy in GI cancer.

关 键 词：替吉奥 化疗 毒副反应 

分 类 号：R735[医药卫生—肿瘤] R730.53[医药卫生—临床医学]